Associations of the Lifestyle for Brain Health index with longitudinal cognition and brain amyloid beta in clinically unimpaired older adults: Findings from the Wisconsin Registry for Alzheimer’s Prevention

Karly A. Cody¹,² | Rebecca L. Koscik¹,²,³ | Claire M. Erickson¹,² | Sara E. Berman¹,² | Erin M. Jonaitis¹,²,³ | Victoria J. Williams¹,² | Kimberly D. Mueller¹,²,³,⁵ | Bradley T. Christian¹,⁶,⁷ | Nathanial A. Chin¹ | Lindsay R. Clark¹,²,⁴ | Tobey J. Betthauser¹,² | Sterling C. Johnson¹,²,³,⁴

¹Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
²Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
³Wisconsin Alzheimer’s Institute, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
⁴Geriatric Research Education and Clinical Center, William S. Middleton Veterans Hospital, Madison, Wisconsin, USA
⁵Department of Communication Sciences & Disorders, University of Wisconsin–Madison, Madison, Wisconsin, USA
⁶Waisman Laboratory for Brain Imaging and Behavior, University of Wisconsin–Madison, Madison, Wisconsin, USA
⁷Department of Medical Physics, University of Wisconsin–Madison, Madison, Wisconsin, USA

Abstract

Introduction: Modifiable health and lifestyle factors increase risk of dementia, but whether modifiable factors, when measured in late-midlife, impact the emergence or progression of Alzheimer’s disease (AD) pathophysiologic or cognitive changes remains unresolved.

Methods: In initially cognitively unimpaired, late middle-aged participants (N = 1215; baseline age, M [standard deviation] = 59.3 [6.7] years) from the Wisconsin Registry for Alzheimer’s Prevention (WRAP), we investigated the influence of the Lifestyle for Brain Health (LIBRA) index, a lifestyle-based dementia risk score, on AD-related cognitive trajectories and amyloid beta (Aβ) plaque accumulation.

Results: Overall, lower baseline LIBRA, denoting healthier lifestyle and lower dementia risk, was related to better overall cognitive performance, but did not moderate apolipoprotein E ε4 or Aβ-related longitudinal cognitive trajectories. LIBRA was not significantly associated with Aβ accumulation or estimated age of Aβ onset.

Discussion: In WRAP, late-midlife LIBRA scores were related to overall cognitive performance, but not AD-related cognitive decline or Aβ accumulation in the preclinical timeframe.

KEYWORDS
amyloid, apolipoprotein E ε4, biomarkers, cognitive impairment, lifestyle, positron emission tomography, preclinical Alzheimer’s disease, risk factors
The pathophysiological progression of Alzheimer’s disease (AD) begins with amyloid beta (Aβ) plaque accumulation and can occur two or more decades before clinical symptom onset. Characterizing this preclinical or pre-symptomatic phase is critical for the development of effective intervention or preventive strategies. With the long prodromal period and current lack of effective treatments, attention has shifted toward preventive strategies focusing on modifiable factors that may prevent or delay the onset of dementia. The availability of neuroimaging and fluid AD biomarkers now provides opportunity to study associations between modifiable risk factors and AD pathophysiological and cognitive changes in the decades preceding dementia, before irreparable brain damage and cognitive symptoms occur.

Longitudinal observational studies of preclinical AD have demonstrated that cognitively unimpaired individuals with elevated Aβ exhibit faster cognitive decline and are at an increased risk for clinical disease progression. Further, recent evidence indicates that the duration of amyloid exposure in these individuals is associated with more rapid cognitive decline and increased tau burden. It remains unclear whether modifiable lifestyle factors, when measured in combination, impact the emergence or progression of AD pathophysiological or cognitive changes. Understanding the associations between modifiable lifestyle factors and longitudinal cognition in the preclinical phase of AD is critical, as modifiable factors constitute potential targets for therapeutics and preventive strategies.

The common co-occurrence of modifiable health and lifestyle factors of dementia and the increasing focus on early intervention have stimulated the development of dementia risk scores, like the Lifestyle for Brain Health (LIBRA) index, which was developed based on a systematic literature review and Delphi consensus. It is a compound score, comprised of 12 modifiable lifestyle factors that are amenable to change and thus reflects one’s prevention potential for dementia. Several population- and patient-based cohort studies have demonstrated that lower LIBRA scores, denoting healthier lifestyle and lower lifestyle-based dementia risk, are associated with better cognitive functioning and lower risk of mild cognitive impairment (MCI) and dementia in mid- and late-life. Whether modifiable lifestyle factors, as indexed by the LIBRA score, interact with genetic risk (e.g., apolipoprotein E [APOE] ε4 genotype) or Aβ burden on preclinical cognitive decline in the context of AD remains to be elucidated.

Therefore, in the present study, we examined whether LIBRA, a well-validated multivariable measure of modifiable lifestyle-based dementia risk, moderates APOE ε4 or Aβ-related longitudinal cognitive decline among late middle-aged, initially unimpaired individuals from the Wisconsin Registry for Alzheimer’s Prevention (WRAP). Additionally, we examined whether LIBRA in late-midlife is associated with Aβ accumulation or estimated age of Aβ onset.

### 2 | METHODS

#### 2.1 | Participants

Data were from individuals enrolled in WRAP, an ongoing longitudinal observational study that follows a cohort of > 1500 asymptomatic (at study entry), late-middle aged adults. The WRAP sample is enriched for family history of AD, with >70% of WRAP participants having a parent with either autopsy-confirmed or probable AD as defined by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association research criteria. The overarching goal of WRAP is to characterize the emergence and progression of AD from late-midlife into old age. Participation in WRAP includes biennial evaluations that involve a physical and health examination, neuropsychological assessment, and optional linked studies for acquisition of neuroimaging or fluid biomarkers of AD pathophysiology. At each study visit, WRAP participants were clinically diagnosed based on National Institute on Aging–Alzheimer’s Association workgroup diagnostic criteria, confirmed through a multi-disciplinary consensus diagnosis panel.

Briefly, diagnoses included cognitively unimpaired, MCI, impaired—not MCI, and dementia. WRAP participants with complete LIBRA factor data were included in the current study (n = 1215; see Figure S1 in supporting information for detailed inclusion/exclusion criteria).

APOE ε4 was genotyped as previously described. Participants were categorized as APOE ε4 carriers (one or two ε4 alleles) or noncarriers (zero ε4 alleles). All subjects provided informed consent and study procedures were approved by the University of Wisconsin–Madison Institutional Review Board and conducted in accordance with the Declaration of Helsinki.

#### 2.2 | Cognition

WRAP participants completed cognitive assessments at their initial study visit and approximately every 2 years thereafter. Longitudinal
cognitive performance was assessed using the Preclinical Alzheimer’s Cognitive Composite (PACC-3), a cognitive composite that has been shown to be sensitive to preclinical $A\beta$ burden.\textsuperscript{6,13,14,24} The WRAP PACC-3\textsuperscript{25} is derived from the Rey Auditory Verbal Learning Test total learning score (RAVLT; Trials 1–5), Wechsler Memory Scale–Revised Logical Memory delayed recall score,\textsuperscript{26} and the Wechsler Adult Intelligence Scale–Revised Digit Symbol test score.\textsuperscript{27}

### 2.3 | Operationalization of the LIBRA score

LIBRA is a weighted sum score (theoretical range = -5.9 to +12.7; with lower scores indicating healthier lifestyle and lower lifestyle-based dementia risk) comprised of 12 modifiable factors that can be targeted by lifestyle interventions and primary prevention. Risk factors include physical inactivity, smoking, depression, hypertension, obesity, diabetes, hypercholesterolemia, coronary artery disease, and renal disease. Protective factors include low-to-moderate alcohol use, high cognitive activity, and healthy diet. In WRAP, longitudinal data on diet was lacking and thus was not included in the overall risk score. The individual LIBRA factors were created based on clinical data from physical examination or self-reported questions and then dichotomized based on previously established cut-offs (Table 1). The LIBRA total score was calculated from the 11 available factors in WRAP using a previously reported approach, in which a weight (positive for presence of risk factors; negative for presence of protective factors; Table 1) was assigned to each factor in accordance with the relative risks from published meta-analyses.\textsuperscript{8,18,28} Table 1 provides an overview of available LIBRA factors, assigned weights, and operationalization in this dataset.

### 2.4 | Positron emission tomography imaging

A subset of participants ($N = 285$) underwent T1-weighted magnetic resonance imaging (MRI; 3T GE Signa 750) as well as $A\beta$ (${\mathrm{[11C]-}}$Pittsburgh compound B [PiB]) positron emission tomography (PET) imaging. Detailed methods for radioligand synthesis and PET and MRI acquisition, processing and quantification, and analysis were implemented as reported previously.\textsuperscript{29,30} $A\beta$ burden was assessed as a global cortical average PiB distribution volume ratio (DVR),\textsuperscript{27} and a previously established threshold of DVR > 1.19 was used to determine $A\beta$ positivity.\textsuperscript{31} Age of $A\beta$ onset and $A\beta$ duration (age at visit – estimated age $A\beta$+), defined as the approximate number of years that an individual has had suprathreshold $A\beta$ positivity, were estimated using a combination of group-based trajectory modeling and Bayes’ theorem.\textsuperscript{6}

### 2.5 | Statistical analyses

Statistical analyses were performed with R version 4.0.5 (The R Foundation). Kruskal–Wallis and chi-squared tests were used to examine baseline differences in demographics and LIBRA factors among three LIBRA risk groups based on LIBRA tertiles (low risk: LIBRA scores between −4.2 and 0; moderate risk: LIBRA scores between 0.1 and 2.0; High risk: LIBRA scores between 2.1 and 8.1; Table 2). To examine whether baseline LIBRA moderates the negative associations of $APOE$ ε4 or $A\beta$ duration with cognitive decline, we modeled longitudinal standardized PACC-3 trajectories using linear mixed effects (LME) models (nlme package, R). Models included age, age$^2$, sex, baseline Wide Range Achievement Test 3rd Edition (WRAT3) reading score, and practice fixed effects (age and WRAT3 centered using baseline means) as well as subject-specific random intercepts and age-related slopes (unstructured covariance).\textsuperscript{6} The first set of LME models ($N = 1215$) included a three-way interaction among baseline LIBRA, $APOE$ ε4 carriage, and age to determine whether lifestyle and genetic risk increase the likelihood of cognitive decline beyond their separate effects (i.e., synergistic effect). A second set of LME models (PiB subset, $N = 285$) examined the combined influence of baseline LIBRA and $A\beta$ duration on longitudinal PACC-3, and included a three-way interaction among baseline LIBRA, $A\beta$ duration, and age. For each set, we followed a backward stepwise approach, removing highest order non-significant interactions sequentially. Two-sided $P$-values <.05 were considered statistically significant, and Akaike information criteria (AIC) statistics were used to determine the model of best fit. Secondary analyses repeated each LME model set using time-varying LIBRA (i.e., LIBRA at each cognitive assessment) to assess whether concurrent LIBRA moderates the negative associations of $APOE$ ε4 carriage or $A\beta$ duration on PACC-3 decline. Associations of baseline LIBRA with $A\beta$ burden and estimated age of $A\beta$ onset were investigated using linear regressions that
The Center for Epidemiologic Studies-Depression Scale was used to measure depressive symptoms. Participants were considered depressed if their sum score \( \geq 16 \).

Hypercholesterolemia was defined as self-reported use of anti-cholinergic medication or, if no self-report, total serum cholesterol \( \geq 240 \text{mg/dL} \).

Renal dysfunction was defined as self-report, mean systolic blood pressure \( \geq 130 \text{mmHg} \) or mean diastolic blood pressure \( \geq 80 \text{mmHg} \).

Depression symptoms. Participants were considered depressed if their sum score \( \geq 16 \).

TABLE 1 Operationalization of LIBRA factors

| Modifiable factor | Definition | Weight$^a$ |
|------------------|------------|------------|
| Low/moderate alcohol use | Self-reported frequency of alcohol use, where low-to-moderate consumption was defined as two drinks or less in a day for men and one drink or less per day for women, including (non-drinkers). | −1.0 |
| Coronary artery disease | Coronary artery disease was based on physician review of self-reported medical history. Coronary artery disease included history of recurrent chest pain with exercise (angina pectoris), history of heart attack (myocardial infarction), or history of cardiac interventions (e.g., angioplasty, stenting, or coronary bypass surgery). | +1.0 |
| Physical inactivity | Self-reported physical activity on CHAMPS questionnaire, where physical inactivity was defined as fewer than 150 minutes of moderate exercise per week. | +1.1 |
| Renal dysfunction | The Chronic Kidney Disease Epidemiology Collaboration equation was used to estimate GFR from serum creatinine and other clinical parameters, and renal dysfunction was defined as GFR \( < 60 \text{mL/min/1.73m}^2 \). | +1.1 |
| Diabetes | Diabetes was determined from self-reported use of anti-diabetic medication or, if no self-report, fasting blood glucose \( \geq 126 \text{mg/dL} \). | +1.3 |
| High cholesterol | Hypercholesterolemia was defined as self-reported use of anti-cholinergic medication or, if no self-report, total serum cholesterol \( \geq 240 \text{mg/dL} \). | +1.4 |
| Smoking | Smoking was defined from self-reported history of smoking at least once in the past month. | +1.5 |
| Obesity | BMI \( \geq 30 \text{kg/m}^2 \) calculated from physical examination at the study visit. | +1.6 |
| Hypertension | Hypertension was defined as self-report of use of anti-hypertensive medication or, if no self-report, mean systolic blood pressure \( \geq 130 \text{mmHg} \) or mean diastolic blood pressure \( \geq 80 \text{mmHg} \). | +1.6 |
| Depression | The Center for Epidemiologic Studies-Depression Scale was used to measure depressive symptoms. Participants were considered depressed if their sum score \( \geq 16 \). | +2.1 |
| High cognitive activity | Games score \( > 4 \), on the Cognitive Activity Scale. | −3.2 |

Abbreviations: BMI, body mass index; CHAMPS, Community Healthy Activities Model Program for Seniors; GFR, glomerular filtration rate; LIBRA, Lifestyle for Brain Health index.

$^a$LIBRA score, composed of available factors in the Wisconsin Registry for Alzheimer’s Prevention (excluding Mediterranean diet, for which data was not available). Positive weights are assigned to risk factors, and negative weights are assigned to protective factors. Total range −5.9 to 12.7; range adjusted to this study −4.2 to 12.7.

covaried age at PiB PET visit, APOE ε4, and time between baseline LIBRA and PiB visit (\( N = 285 \)). In the subset with two or more PiB scans (\( N = 178 \)), we ran similar models using annualized PiB DVR change to examine whether baseline LIBRA was associated with Aβ accumulation rate.

3 | RESULTS

3.1 | Participants

Baseline sample characteristics and frequency of LIBRA factors are presented overall and by baseline LIBRA risk groups (Table 2). Over a median (interquartile range [IQR]) of 6.9 (3.4–9.3) years of cognitive follow-up, 1181 (97.2%) participants remained unimpaired and 31 (2.6%) participants progressed to MCI or dementia. Individuals in the high LIBRA risk group, had fewer years of education and worse WRAT3 performance compared to individuals in the low LIBRA risk group. The proportion of LIBRA risk factors increased stepwise across LIBRA risk groups (e.g., low risk < moderate risk < high risk). Physical inactivity, diabetes, high cholesterol, smoking, obesity, hypertension, and depression were more common risk factors in the high LIBRA risk group, and high cognitive activity was a more common protective LIBRA factor in the low LIBRA risk group. No differences in PiB PET measures of Aβ were observed across LIBRA risk groups (Table 2).

3.2 | LIBRA and longitudinal cognitive decline

Of primary interest was whether baseline LIBRA moderates the negative association of APOE ε4 or Aβ-related longitudinal decline. In the LME models (\( N = 1215 \), up to six cognitive assessments per participant) investigating late-midlife longitudinal PACC-3, the baseline LIBRA \( \times \) APOE ε4 carriage \( \times \) age interaction provided no statistical evidence that baseline lifestyle attenuates APOE ε4-related cognitive decline (LIBRA \( \times \) APOE ε4 carriage \( \times \) age\(^2\), \( P = .18 \); LIBRA \( \times \) APOE ε4 carriage \( \times \) age, \( P = .76 \); Table S1 in supporting information). In the final reduced model (Table 3, Figure 1A), lower (i.e., healthier) baseline LIBRA was associated with better average PACC-3 performance (\( P < .001 \)) and both the age and age\(^2\) interactions with APOE ε4 carriage indicated significantly faster PACC-3 decline among APOE ε4 carriers. The parallel LME models in the PiB subset (\( N = 285 \), up to five cognitive assessments per participant) examining the interactive associations of baseline LIBRA and baseline Aβ duration on longitudinal PACC-3 did not reveal a
| Characteristics                              | Total sample (N = 1215) | Baseline LIBRA risk groups\(^a\) | Group P-value\(^b\) | Pairwise differences\(^b\) |
|--------------------------------------------|-------------------------|----------------------------------|---------------------|---------------------------|
| **Age at LIBRA baseline**                 |                         |                                  |                     |                           |
| 59.3 (6.7)                                 | 59.6 (7.0)              | 59.4 (6.6)                       | 58.8 (6.6)          | .38                       |
| **No. of study visits, Median [range]**    |                         |                                  |                     |                           |
| 4 [1 to 6]                                 | 4 [1 to 6]              | 4 [1 to 6]                       | 4 [1 to 6]          | .17                       |
| **Years of cognitive follow-up**          |                         |                                  |                     |                           |
| 6.4 (3.5)                                  | 6.6 (3.4)               | 6.4 (3.5)                        | 6.2 (3.5)           | .16                       |
| **Clinical diagnosis at most recent visit**|                         |                                  |                     |                           |
| Unimpaired                                 | 1181 (97.2%)            | 388 (98.4%)                      | 415 (96.7%)         | 378 (96.4%)               | .50                       |
| Mild cognitive impairment                  | 27 (2.2%)               | 5 (1.3%)                         | 12 (2.8%)           | 10 (2.6%)                 |                           |
| Dementia                                   | 4 (0.3%)                | 1 (0.3%)                         | 1 (0.2%)            | 2 (0.5%)                  |                           |
| Impaired, other                            | 3 (0.2%)                | 0 (0%)                           | 1 (0.2%)            | 2 (0.5%)                  |                           |
| **APOE ε4 carriers**                       | 469 (38.6%)             | 143 (36%)                        | 168 (39%)           | 158 (40%)                 | .49                       |
| **Parental family history of AD\(^c\)**   | 924 (76%)               | 291 (74%)                        | 327 (76%)           | 306 (78%)                 | .38                       |
| **Female**                                 | 853 (70.2%)             | 295 (75%)                        | 290 (68%)           | 268 (68%)                 | .05                       |
| **WRAT3 reading score**                    | 105.8 (9.5)             | 107.3 (9.0)                      | 106.5 (9.0)         | 103.5 (10.1)              | <.001                     |
| **Years of education**                     | 15.8 (2.3)              | 16.2 (2.2)                       | 15.9 (2.2)          | 15.3 (2.2)                | <.001                     |
| **Baseline LIBRA factors\(^d\)**          |                         |                                  |                     |                           |
| Low/moderate alcohol consumption           | 1037 (85.3%)            | 352 (89%)                        | 387 (90%)           | 298 (76%)                 | <.001                     |
| Cardiovascular disease                     | 28 (2.3%)               | 5 (1.3%)                         | 10 (2.3%)           | 13 (3.3%)                 | .16                       |
| Physical inactivity                        | 400 (32.9%)             | 47 (12%)                         | 158 (37%)           | 195 (50%)                 | <.001                     |
| Renal dysfunction                          | 88 (7.2%)               | 21 (5.3%)                        | 29 (6.8%)           | 38 (9.7%)                 | .06                       |
| Diabetes                                   | 88 (7.2%)               | 6 (1.5%)                         | 29 (6.8%)           | 53 (14%)                  | <.001                     |
| High cholesterol                           | 193 (15.9%)             | 38 (9.6%)                        | 60 (14%)            | 95 (24%)                  | <.001                     |
| Smoking                                    | 74 (6.1%)               | 6 (1.5%)                         | 16 (3.7%)           | 52 (13%)                  | <.001                     |
| Obesity                                    | 440 (36.2%)             | 51 (13%)                         | 115 (27%)           | 274 (70%)                 | <.001                     |
| Hypertension                               | 648 (53.3%)             | 93 (24%)                         | 234 (55%)           | 321 (82%)                 | <.001                     |
| Depression                                 | 146 (12.0%)             | 14 (3.6%)                        | 25 (5.8%)           | 107 (27%)                 | <.001                     |
| High cognitive activity                    | 271 (22.3%)             | 198 (50%)                        | 57 (13%)            | 16 (4.1%)                 | <.001                     |
| **Baseline LIBRA score**                   | 0.9 (2.2)               | –1.5 (1.1)                       | 0.9 (0.6)           | 3.4 (1.2)                 | <.001                     |
| **PiB PET subset**                         | 285 (23.5%)             | 96 (33.7%)                       | 115 (40.4%)         | 74 (25.9%)                | .10                       |
| **Age at most recent Aβ PiB PET**          | 67.1 (6.6)              | 67.9 (6.6)                       | 67.0 (6.4)          | 66.2 (6.9)                | .29                       |
| **Global PiB DVR**                         | 1.15 (0.20)             | 1.18 (0.23)                      | 1.15 (0.20)         | 1.13 (0.17)               | .55                       |
| **Aβ positivity at most recent PiB visit\(^e\)** | 67 (24%)            | 27 (28%)                         | 26 (23%)            | 14 (18.9%)                | .36                       |
| Participants with > 1 PiB PET visits       | 178 (62%)               | 64 (66%)                         | 65 (57%)            | 49 (66%)                  | .68                       |
| **Years of PiB PET follow-up\(^f\)**       | 6.4 (2.3)               | 6.7 (2.1)                        | 6.6 (2.1)           | 5.8 (2.5)                 | .45                       |
| **Annualized change in global PiB DVR\(^f\)** | 0.006 (0.015)          | 0.008 (0.017)                    | 0.003 (0.013)       | 0.006 (0.015)             | .35                       |

Note: Values are present as Mean (SD) or No. (%) unless otherwise indicated.

Abbreviation: Aβ, amyloid beta; AD, Alzheimer’s disease; APOE, apolipoprotein E; DVR, distribution volume ratio; LIBRA, Lifestyle for Brain Health index; PiB, Pittsburgh compound B; PET, positron emission tomography; WRAT3, Wide Range Achievement Test (3rd edition).

\(^a\) LIBRA risk groups were determined using baseline LIBRA tertiles: low risk was defined as LIBRA scores between –4.2 and 0, moderate risk was defined as LIBRA scores between 0.1 and 2.0, high risk was defined as LIBRA scores between 2.1 and 8.1.

\(^b\) Statistical tests: \(\chi^2\) or Fisher exact test for categorical variables, Kruskal–Wallis rank sum test for continuous variables; P-value for difference between Baseline LIBRA risk groups. For group tests with P < .05, unadjusted pairwise post hoc differences are reported.

\(^c\) Four participants were missing information on parental family history of AD.

\(^d\) See Table 1 for the details on the operationalization of LIBRA factors.

\(^e\) Aβ positivity was defined as global PiB DVR > 1.19.

\(^f\) Values shown for subset (N = 178) with longitudinal (>1) PiB PET visits.
significant LIBRA × Aβ duration × age interaction (LIBRA × Aβ duration × age², P = .67; LIBRA × Aβ duration × age, P = .95, Table S2 in supporting information). In the final reduced model in the PiB subset (Table 3, Figure 1B), baseline LIBRA was associated with better PACC-3 performance (P < .001) and both the linear and quadratic interactions between Aβ duration and age indicated significantly faster rates of PACC-3 decline among those who were Aβ positive longer. Results were similar when investigating the associations of concurrent LIBRA with APOE ε4 carriage and Aβ duration on PACC-3 decline (Tables S3–S4 in supporting information).

### 3.3 LIBRA and Aβ burden

A secondary goal was to examine whether baseline LIBRA was associated with Aβ plaque accumulation. After adjusting for age at the most recent PiB visit, APOE ε4 carriage, and time between baseline
LIBRA and PiB visit, there was no evidence for a cross-sectional association of baseline LIBRA with global PiB DVR \( (N = 285, \beta \text{ [standard error (SE)]} = -0.01 [0.01], P = .11) \) or estimated age of \( A_\beta \) onset \( (\hat{\beta} \text{ [SE]} = 0.23 [0.33], P = .49; \text{Table S5 in supporting information}) \). In the subset with multiple PiB scans \( (N = 178; \text{years of PiB follow-up, Mean [standard deviation (SD)]} = 6.4 [2.3]) \), there was no significant association between LIBRA and the annualized change in global PiB burden \( (\hat{\beta} \text{ [SE]} = -0.0003 [0.0006], P = .54; \text{Table S5}) \). Results were similar when investigating the associations of \( A_\beta \) PET measures across LIBRA tertiles (Figure 2, Table 2).

**4 | DISCUSSION**

This longitudinal study investigated the association of health and lifestyle, quantified using a multivariable lifestyle-based dementia risk score (LIBRA), with cognitive trajectories and AD pathophysiology in initially cognitively unimpaired, late-middle aged adults enriched for risk of AD. Baseline LIBRA scores, reflecting a brain-healthy late-midlife lifestyle, were associated with better overall cognitive performance, but not the rate of cognitive decline or the accumulation of \( A_\beta \) plaques. Additionally, baseline LIBRA did not moderate the negative associations of \( \text{APOE} \epsilon 4 \) carriage or \( A_\beta \) duration with longitudinal cognitive decline over the duration of the study. Collectively, these findings suggest that a healthy lifestyle in late-midlife is important for overall cognition, but may not influence \( A_\beta \) accumulation or attenuate \( \text{APOE} \epsilon 4 \) or \( A_\beta \)-related cognitive decline in those unimpaired at baseline.

These results are in line with previous population and patient-based cohort studies showing that LIBRA scores are related to cognitive functioning, but not the individual course of cognitive decline. In our AD risk–enriched sample, there was no evidence for synergy between LIBRA and \( \text{APOE} \epsilon 4 \) carriage \( \text{LIBRA} \times \text{APOE} \epsilon 4 \text{ carriage} \times \text{age was not significant [NS]} \). These findings add to a previous study of LIBRA, demonstrating no significant interactions between midlife LIBRA and \( \text{APOE} \epsilon 4 \) carriage on risk of MCI or dementia,\(^{15} \) and suggest that LIBRA in late-midlife does not moderate \( \text{APOE} \epsilon 4 \)-related cognitive decline in the early pre-symptomatic phase of AD. Additionally, we found no evidence for synergy between LIBRA and \( A_\beta \) duration \( \text{LIBRA} \times A_\beta \text{ duration} \times \text{age was NS} \) on longitudinal cognitive decline. These results align with recent studies suggesting that lifestyle and cardiovascular risk factors embodied by LIBRA may generally increase risk for cognitive impairment and dementia, but are not specific to AD.\(^{33-37} \) Notably, when accounting for the negative influence of \( \text{APOE} \epsilon 4 \) and \( A_\beta \) duration on cognitive decline, baseline LIBRA remained strongly associated with better overall cognitive performance. Supplemental analyses examining concurrent lifestyle revealed similar results. Together, these findings suggest that health and lifestyle are important for general cognition throughout mid- and late-life, but may not impact early AD-related cognitive trajectories.

In WRAP, we did not observe a clear association between baseline LIBRA and \( A_\beta \) burden; analyses failed to show an association between markers of early \( A_\beta \) development and lifestyle in late-midlife. These findings are consistent with several studies among cognitively unimpaired individuals that did not find a correlation between vascular health and \( A_\beta \) burden.\(^{38-40} \) For example, the largest study to date of preclinical AD involving cognitively healthy people with \( A_\beta \) imaging showed that elevated brain \( A_\beta \) was associated with \( \text{APOE} \epsilon 4 \) carriage but not with multiple self-reported lifestyle risk factors encompassed by the LIBRA score (e.g., physical activity, body mass index, alcohol intake, smoking).\(^{37} \) Our results, showing a lack of an association between LIBRA and brain \( A_\beta \) among cognitively normal
late-middle aged adults, in combination with a recent cross-sectional population-based study showing an association of LIBRA with non-AD specific measures of brain health (e.g., white matter hyperintensities and brain atrophy) suggest that lifestyle, as indexed by LIBRA, may play an important role in general brain health, but may not influence early AD-related brain changes.

These results are best understood in the context of the study sample. With the relatively long period of follow-up and enrichment for AD risk, WRAP is uniquely powered to detect AD-related changes in late-middle age during the pre-symptomatic timeframe. Notably, in the current study, <5% of individuals progressed to clinical levels of impairment. Thus, studies with a greater proportion of individuals progressing to MCI or dementia will be needed to fully elucidate the moderating role of lifestyle on AD-related clinical progression in the symptomatic timeframe. Additionally, it is worth considering that given the preclinical timeframe (≥60 years of age at baseline) and limited sample with elevated Aβ, we may have been underpowered to detect an interaction between LIBRA and Aβ-related cognitive decline. As Aβ accumulates over years to decades, it will be important to continue to examine the associations between midlife lifestyle, Aβ accumulation, and cognition over longer periods of follow-up.

The comprehensive study visits in WRAP made it possible to operationalize LIBRA factors based on clinical data from physical examination in combination with self-reported medical history. While data on most LIBRA factors were available, the absence of diet, which is a protective LIBRA factor, could have weakened the overall LIBRA score. Also, it remains unknown whether or the extent to which pharmacological treatment of LIBRA factors may have influenced our findings. Additionally, participation requires serial cognitive and health assessments, which may have resulted in a sample consisting of individuals with better overall health and lifestyle, and consequently, those with a higher range of lifestyle-related dementia risk may be underrepresented in the study sample. Finally, it is worth noting that WRAP reflects the demographics (e.g., primarily White) and health characteristics (e.g., rates of obesity, hypertension, diabetes) of the Wisconsin population, which reduces the generalizability of our findings. Larger, more representative samples will be necessary to understand the impact of lifestyle on AD-related cognitive changes in late-middle age.

5 | CONCLUSIONS

In this late-middle aged AD risk–enriched sample, lower LIBRA scores, indicating a brain-healthy lifestyle, were strongly associated with better overall cognitive performance when accounting for the negative influence of APOE e4 and Aβ duration on preclinical cognitive decline. There was no evidence that LIBRA in late-middle age was related to Aβ accumulation or moderated APOE e4 or Aβ-related cognitive decline. Lifestyle, as indexed by LIBRA, may not be related to pathophysiologic or cognitive changes in the early, preclinical stages of the AD continuum; whether lifestyle contributes to AD progression later in the disease trajectory warrants further study.

ACKNOWLEDGMENTS

This publication was supported by NIH R01AG027161 (Johnson), NIH RO1AG021155 (Johnson), AARF 19614533 (Bethhauser), NICHD P50HD105353 (Qiang), and S10 OD025245-01 (Christian), and the University of Wisconsin Institute for Clinical and Translational Research NIH UL1TR002375 (Cody). We extend our deepest thanks to the WRAP participants and staff for their invaluable contributions to the study.

CONFLICTS OF INTEREST

Dr. Johnson has participated on an advisory panel for and received an equipment grant from Roche Diagnostics, and he has received support (sponsoring of an observational study and provision of precursor for tau imaging) from Cerveau Technologies. No other disclosures were reported. Author disclosures are available in the supporting information.

ORCID

Karly A. Cody https://orcid.org/0000-0001-5996-2560

REFERENCES

1. Jack CR, jr., Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain. 2009;132(Pt 5):1355-1365. doi: 10.1093/brain/awp062
2. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280-292. doi: 10.1016/j.jalz.2011.03.003
3. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795-804. doi: 10.1056/NEJMoa1202753
4. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357-367. doi: 10.1016/s1474-4422(13)70044-9
5. Jack CR, jr, Bennett DA, Blennow K, Research Framework NIA-AA. Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018
6. Koscik RL, Bethhauser TJ, Jonaitis EM, et al. Amyloid duration is associated with preclinical cognitive decline and tau PET. Alzheimers Dement. 2020;12(1). doi: 10.1002/dad.121007
7. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788-794. doi: 10.1016/s1474-4422(14)70136-x
8. Deckers K, van Boxtel MP, Schiepers OJ, et al. Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. Int J Geriatr Psychiatry. 2015;30(3):234-246. doi: 10.1002/gps.4245
9. Klivipieto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol. 2018;14(11):653-666. doi: 10.1038/s41582-018-0070-3
10. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446. doi: 10.1016/s0140-6736(20)30367-6
11. Clark LR, Racine AM, Koscik RL, et al. Beta-amyloid and cognitive decline in late middle age: findings from the Wisconsin Registry for
Alzheimer’s Prevention study. Alzheimers Dement. 2016;12(7):805-814. doi: 10.1016/j.jalz.2015.12.009
12. Bilgel M, Koskic RL, An Y, et al. Temporal order of Alzheimer’s disease-related cognitive marker changes in BLSA and WRAP longitudinal studies. J Alzheimers Dis. 2017;59(4):1335-1347. doi: 10.3233/JAD-170448
13. Mormino EC, Papp KV, Rentz DM, et al. Early and late change on the preclinical Alzheimer’s cognitive composite in clinically normal older individuals with elevated amyloid beta. Alzheimers Dement. 2017;13(9):1004-1012. doi: 10.1016/j.jalz.2017.01.018
14. Donohue MC, Sperling RA, Petersen R, et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317(22):2305-2316. doi: 10.1001/jama.2017.6669
15. Deckers K, Barbera M, Köhler S, et al. Long-term dementia risk prediction using the LIBRA score: a 30-year follow-up of the CAIDE study. Int J Geriatr Psychiatry. 2020;35(2):195-203. doi: 10.1002/gps.5235
16. Heger IS, Deckers K, Schrat MT, et al. Associations of the Lifestyle For Brain Health Index with structural brain changes and cognition: results from the maastricht study. Neurology. 2021;97(13):e1300-e1312. doi: 10.1212/WNL.0000000000012572
17. Pons A, LaMonica HM, Mowszowski L, Kohler S, Deckers K, Naismith SL. Utility of the LIBRA Index in relation to cognitive functioning in a clinical health seeking sample. J Alzheimers Dis. 2018;62(1):373-384. doi: 10.3233/JAD-170731
18. Schiepers OJG, Kohler S, Deckers K, et al. Lifestyle for Brain Health (LIBRA): a new model for dementia prevention. Int J Geriatr Psychiatry. 2018;33(3):167-175. doi: 10.1002/gps.4700
19. Vos SJB, van Boxtel MPJ, Schiepers OJG, et al. Modifiable risk factors for prevention of dementia in midlife, late life and the oldest-old: validation of the LIBRA Index. J Alzheimers Dis. 2017;58(2):537-547. doi: 10.3233/JAD-161208
20. Johnson SC, Koscik RL, Jonaitis EM, et al. The Wisconsin Registry for Alzheimer’s Prevention: a review of findings and current directions. Alzheimers Dement (Amst). 2018;10:130-142. doi: 10.1016/j.jad.2017.11.007
21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease. Report of the NINCDS-ADRD A Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer Disease. 1984;34(7):939-939. doi: 10.1212/WNL.0000000000001130
22. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270-279. doi: 10.1016/j.jad.2011.03.008
23. Johnson SC, La Rue A, Hermann BP, et al. The effect of TMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE epsilon3/epsilon3 genotype. Alzheimers Dement. 2011;7(4):456-465. doi: 10.1016/j.jalz.2010.11.012
24. Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):861-970. doi: 10.1001/jamaneurol.2014.803
25. Jonaitis EM, Koscik RL, Clark LR, et al. Measuring longitudinal cognition: individual tests versus composites. Alzheimers Dement (Amst). 2019;11:74-84. doi: 10.1016/j.jad.2018.11.006
26. Wechsler D. WMS-R: Wechsler Memory Scale-Revised. Psychological Corporation; 1987.
27. Wechsler D. Wechsler Adult Intelligence Scale. 3rd ed. The Psychological Corporation; 1997.
28. Anstey KJ, Cherbuin N, Herath PM. Development of a new method for assessing global risk of Alzheimer’s disease for use in population health approaches to prevention. Prev Sci. 2013;14(4):411-421. doi: 10.1007/s11121-012-0313-2
29. Sprecher KE, Bendlin BB, Racine AM, et al. Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. Neurobiol Aging. 2015;36(9):2568-2576. doi: 10.1016/j.neurobiolaging.2015.05.004
30. Bethhauser TJ, Cody KA, Zammit MD, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand. J Nucl Med. 2019;60(1):93-99. doi: 10.2967/jnumed.118.209650
31. Racine AM, Clark LR, Berman SE, et al. Associations between performance on an abbreviated CogState battery, other measures of cognitive function, and biomarkers in people at risk for Alzheimer’s disease. J Alzheimers Dis. 2016;54(4):1395-1408. doi: 10.3233/JAD-160528
32. Deckers K, Kohler S, Ngandu T, et al. Quantifying dementia prevention potential in the FINGER randomized controlled trial using the LIBRA prevention index. Alzheimers Dement. 2021;17(7):1205-1212. doi: 10.1002/alz.12281
33. Dhana K, Evans DA, Rajan KB, Bennett DA, Morris MC. Healthy lifestyle and the risk of Alzheimer’s dementia: findings from 2 longitudinal studies. Neurology. 2020;95(4):e374-e83. doi: 10.1212/NWNL.0000000000009816
34. Lane CA, Barnes J, Nicholas JM, et al. Associations between vascular risk across adulthood and brain pathology in late life: evidence from a British Birth Cohort. JAMA Neurol. 2020;77(2):175-183. doi: 10.1001/jamanetworkneurology.2019.3774
35. Kemppainen N, Johansson J, Teuho J, et al. Brain amyloid load and its associations with cognition and vascular risk factors in FINGER Study. Neurology. 2018;90(3):206. doi: 10.1212/WNL.0000000000004827
36. Vemuri P, Knopman DS, Lesnick TG, et al. Evaluation of amyloid protective factors and alzheimer disease neurodegeneration protective factors in elderly individuals. J Alzheimers Neurol. 2017;74(6):718-726. doi: 10.1001/jama.journalneurology.2017.0244
37. Sperling RA, Donohue MC, Raman R, et al. Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol. 2020;77(6):735-745. doi: 10.1001/jamanetworkneurology.2020.0387
38. Bos I, Vos SJF, Schindler SE, et al. Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer’s disease. Alzheimers Dement. 2019;15(9):1149-1159. doi: 10.1016/j.jalz.2019.04.015
39. Pettigrew C, Soldan A, Wang J, et al. Association of midlife vascular risk and AD biomarkers with subsequent cognitive decline. Neurology. 2020;95(23):e3093. doi: 10.1212/WNL.0000000000010946
40. Vemuri P, Lesnick TG, Przybylski SA, et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain. 2015;138(Pt 3):761-771. doi: 10.1093/brain/awu393
41. Behavioral Risk Factor Surveillance System Survey Data: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Cody KA, Koscik RL, Erickson CM, et al. Associations of the Lifestyle for Brain Health index with longitudinal cognition and brain amyloid beta in clinically unimpaired older adults: Findings from the Wisconsin Registry for Alzheimer’s Prevention. Alzheimers Dement. 2022;14:e12351. https://doi.org/10.1002/dad2.12351